Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Courses Quicksearch

Search Now!

Courses


Course List
  • A Cut Above the Rest: Coordinating Perioperative Care Between Anesthesiologists and the PH Team

    Course ID: 2918
    Course Author: Traci Housten
    Course Author: Todd Kolb

    As patients with pulmonary hypertension live longer and better, it is inevitable that more PH patients will choose to undergo elective procedures or require emergency surgical procedures. Any operative procedure will require the involvement of several hospital departments. Thoughtful communication and collaboration between Anesthesia staff and the PH Team is crucial to develop a safe and proactive perioperative plan for the PH patient.


  • A Selective TGFß Ligand Trap Attenuates Pulmonary Arterial Hypertension

    Course ID: 2863




  • Advance Care Planning: Talking to Patients and their Families about Advance Directives

    Course ID: 2912

    Despite advances in therapies, PH remains a progressive illness without a cure and we are limited to treating symptoms with the goal of quality-of-life enhancements. Palliative medicine is, by definition, a multidisciplinary approach to specialized medical care for people with serious illnesses. It focuses on providing patients with relief from the symptoms, pains, and physical/mental stress that accompany a serious illness. This session will provide an overview of palliative medicine, its benefits and limitations and how to incorporate a palliative care approach to the management of patients with PH.


  • CTEPH and CTED: Diseases that Hide in Plain Sight

    Course ID: 2830
    Course Author: Paul R. Forfia
    Course Author: Frances Rogers

    Chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic disease (CTED) are chronic sequelae of venous thromboembolism. In both cases, partial or complete obstruction of the pulmonary circulation leads to a syndrome of varying degrees of elevation of pulmonary arterial impedence, right ventricular afterload mismatch, dead space ventilation and hypoxemia. This session will highlight the salient as well as the subtle clinical and physiologic manifestations of this spectrum of disease. Often, the diagnosis evades initial testing, however with awareness, sufficient clinical suspicion, and proper application of imaging and physiologic testing, the ‘hidden’ diagnosis is easily uncovered.


  • CTEPH: Surgical Versus Medical Patient

    Course ID: 2844
    Course Author: William Auger

    The identification of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is essential as this is a potentially curable form of pulmonary hypertension. This course will highlight the rationale and recommendation for screening all pulmonary hypertensive patients for CTEPH, and will outline the evaluation algorithm for establishing the diagnosis. Working with an experienced PTE surgery center to ascertain whether or not the chronic thromboembolic disease is operable will be emphasized. For those patients with nonsurgical disease, the treatment options of balloon pulmonary angioplasty and pulmonary hypertension targeted medical therapy will be reviewed.


  • Don't Be in Denial: Insurance and Disability Issues

    Course ID: 2772
    Course Author: Maribeth Duncan
    Course Author: Sharon Jones

    Assisting PH patients to get expensive medications or assisting them with disability can be a daunting task. Denial of PAH medications and disability benefits are unfortunately inevitable for many patients, and knowledge and skill is needed to overcome these obstacles. Learn tips to avoid denials and how to successfully win appeals, in addition to other resources available to assist patients with insurance and disability challenges.


  • Etiologies of PH Across the World

    Course ID: 2809
    Course Author: Christopher Barnett
    Course Author: Ghazwan Butrous
    Course Author: Vinicio de Jesus Perez
    Course Author: Erik Swenson

    This session will focus on four common causes of PAH around the world. From a global perspective, schistosomiasis is the most common cause of PH, with HIV and chronic high-altitude exposure closely behind. Drug and toxin exposure, however, has been identified as a specific problem in the western world. This class will highlight the key features of these particular types of PH/PAH, review both established and emerging paradigms, and discuss their implications on a global platform.


  • Evaluation and Management of Connective Tissue Disease-Associated Interstitial Lung Disease

    Course ID: 2928
    Course Author: Aryeh Fischer

    There are complex interactions between connective tissue disease (CTD) and interstitial lung disease (ILD), particularly in the PH patient. Clinicians that care for these patients will benefit from a deeper understanding of CTD and the ILD aspects of this diverse spectrum of disease. There are many clinical dilemmas to address and this course will focus on an approach to the evaluation and management of CTD-associated ILD.


  • Every Breath Counts: When to Involve Palliative Care

    Course ID: 2829
    Course Author: Stephen Mathai
    Course Author: Allyson Rupp

    Palliative medicine is, by definition, a multidisciplinary approach to specialized medical care for people with serious illnesses.This session will provide an overview of palliative medicine, its benefits and limitations and how to incorporate a palliative care approach into the management of patients with PH.


  • FDA-Approved Treatments for WHO Group 1 PH (PAH)

    Course ID: 2933
    Course Author: Vallerie McLaughlin

    WHO Group 1 PH Treatment Course Image
    Since 1995, more than a dozen WHO Group 1 PH (PAH, pulmonary arterial hypertension) targeted oral, inhaled, and infused therapies have been approved by the U.S. Food & Drug Administration. In this session, the mechanistic pathways of current FDA-approved targeted therapies, clinical considerations in selecting an initial PAH therapy, and goals of medical therapy will be discussed.


  • From Bench to Bedside: Which Novel Pathways are Most Likely to be Harnessed Therapeutically in the Next 25 Years?

    Course ID: 2814
    Course Author: Eric Austin

    The past 30 years have produced tremendous advancements in the field of pulmonary hypertensive vascular disease (PHVD), particularly in pulmonary hypertension. The resultant improvements have bolstered patient quality of life and survival rates. In concert with this progress, there has been a renewed international effort amongst pediatric-focused clinicians to identify the similarities and differences between adult and pediatric patients and to highlight areas unique to the pediatric patient. This class will discuss these similarities and differences, with a particular emphasis on the Panama Classification for Pediatric Pulmonary Hypertensive Vascular Disease, and a focus its relevance to the pediatric patient.


  • Here We Grow Again: Regenerative Medicine

    Course ID: 2917
    Course Author: Duncan J. Stewart

    The fundamental problem in pulmonary arterial hypertension is a loss of lung blood vessels, such that the lung is no longer able to accommodate the cardiac output. Therefore, transformative improvement in pulmonary hemodynamics will require the repair or regeneration of lung microcirculation. This could be accomplished with the use of endothelial progenitor cells together with genetic manipulations or in combination with proteins or matrix. This session will provide an overview of the field, and review the challenges and opportunities of a regenerative medical therapy for this disease.


  • How to Follow Up with Your Patient

    Course ID: 2938
    Course Author: Peter Leary

    How to Follow-up with Your Patient Course Image
    This educational activity will allow participants to a) summarize risk stratification for the PH patient; b) describe recommended measures used in clinic to monitor disease progression; and c) summarize guideline recommendations on follow-up of the low-, moderate-, and high-risk patient.


  • How to Know When to Escalate PAH Therapy

    Course ID: 2960
    Course Author: Ronald Oudiz

    How to Know When To Escalate Therapy - Ron Oudiz,
    At the conclusion of this CME educational activity, participants will be able to describe recommended measures used to monitor disease progression; describe risk stratification in PAH; compare initial treatment strategies for low-, moderate-, and high-risk patients; and compare two expert consensus recommendations on PAH clinical management.


  • How to Know Your Patient Is Optimally Managed

    Course ID: 2949
    Course Author: Zeenat Safdar

    Optimal Management of PH Course Image
    Despite the robust therapeutic development since the 1990s, pulmonary hypertension (PH) remains a progressive, incurable disease. In this CME educational activity, Zeenat Safdar, MD, MS, reviews a) the clinical measures correlated with PH disease progression; and b) summarizes expert recommendations for following a stable PH patient.


  • Imaging in PH: What Can a Picture Tell You?

    Course ID: 2817
    Course Author: John Ryan

    This course will discuss the role of imaging technology in the diagnostic and management process of pulmonary hypertension, specifically as it pertains to pulmonary arterial hypertension (PAH). Most patients are initially diagnosed using echocardiograms, however, in order to develop a specialized treatment plan more extensive imaging technologies such as CT, MRI, and PET scans are needed.


  • Interesting and Challenging Cases in PH

    Course ID: 2823

    The intricate manifestations of pulmonary hypertension can present many challenges. Participants in this educational activity will learn how to properly evaluate a patient for PH. This session also discusses in detail, the complex decisions surrounding PH treatment and the significance of right heart catheterization.


  • Interstitial Lung Disease in Systemic Sclerosis

    Course ID: 2927
    Course Author: Flavia Castelino

    Interstitial Lung Disease (ILD) is an important cause of morbidity and mortality in scleroderma patients. This presentation will discuss the clinical evaluation, diagnosis and management of scleroderma interstitial lung disease (SSc-ILD). It will cover the pathogenesis of scleroderma, new treatment targets and current clinical trials in SSc-ILD. Clinical cases will be used to illustrate key points in the evaluation and management of SSc-ILD.


  • Is It PAH or Not: Diagnostic Challenges

    Course ID: 2816
    Course Author: Ioana Preston

    While idiopathic pulmonary arterial hypertension is a rare disease, general PH often complicates other pulmonary and cardiovascular diseases and is a relatively common entity. Significant differences and similarities exist between the five groups of PH, as defined by the World Health Organization. However, without clinical context and noninvasive tests, there is no sufficient evidence to provide an accurate diagnosis. This class will focus on the how to differentiate between the various PH groups and how to utilize integrative tests to produce an accurate and effective diagnosis and treatment plan.


  • Keep Calm and Breathe On: Oxygen Use in PH

    Course ID: 2743
    Course Author: Tonya Zeiger




  • Management of PH in the ICU

    Course ID: 2821
    Course Author: Yon Sung

    The management of critically ill patients with pulmonary hypertension can be particularly challenging as many of the treatments used in the ICU setting can exacerbate PH and right heart failure. In this class, we will review the unique aspects of the physiology of critically ill PH patients, which will then inform our approach to management. Specifically, we will discuss the role of invasive hemodynamic monitoring, the advantages and disadvantages of specific vasoactive medications, and the indications for pulmonary vasodilators in the acute setting.


  • Management of PH in the ICU

    Course ID: 2935
    Course Author: Todd Bull

    Management of PH in the ICU by Todd Bull, MD Cours
    WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a rare, progressive disease characterized by increased pulmonary artery pressure and pulmonary vascular resistance (PVR). Increases in PVR places great stress on the right ventricle, normally a thin-walled, trabeculated, roughly triangulated structure. It is designed to pump into a low-impedance, high-capacitance pulmonary circulation system, which is not the case in PAH. Acutely ill patients need to hemodynamic compromise addressed quickly and effectively, to restore oxygenation, treat volume overload, and restore organ perfusion. Frequently employed strategies—including systemic blood pressure, cardiac output, hypervolemic, arrhythmia, ventilator management—should be approached differently given the high-impedance, low-capacitance nature of the diseased pulmonary circulation to improve patient outcomes. This session will review the normal function of the pulmonary vascular bed; describe the impact of sudden increases in RV after load on cardiac output; describe the impact of hypercarbia, hypoxia, and mechanical ventilation on PVR; discuss two common cardiac arrhythmias that can contribute to critical illness in patients with PAH; and discuss strategies to enhance RV-pulmonary artery interaction in critical illness.


  • PH Group 2: Cases and Challenges

    Course ID: 2970
    Course Author: Myung Park




  • PH Group 3: Cases and Challenges

    Course ID: 2819
    Course Author: Oksana Shlobin

    This session will provide a case-centered update on pathogenesis and epidemiology and significance of pulmonary hypertension in parenchymal lung disease. The currently available treatment data and ongoing clinical trials will be discussed.


  • PH In Its Most Common Forms: Clinical Vignettes for WHO Groups 1, 2, and 4

    Course ID: 2915
    Course Author: Vinicio de Jesus Perez
    Course Author: Bonnie Hudak
    Course Author: Tim Lahm

    This information-intensive, clinical vignette provides an overview of pulmonary hypertension as it most commonly presents itself using clinical case studies. This previously recorded live webinar presents and examines WHO Groups I, II, and IV, offering an interesting perspective on topics in health care barriers, common diagnostic pitfalls, and the complexities of pediatric PH.


  • PHD2 Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension Recapitulating Clinical PAH

    Course ID: 2864




  • Panel Discussion: Enhancing Access to Drugs in Developing Countries, Challenges of Making Generic Drugs Available in Developing Countries

    Course ID: 2809
    Course Author: Steven Kawut
    Course Author: Mona Selej
    Course Author: Ghazwan Butrous
    Course Author: Talant Sooronbaev

    While idiopathic pulmonary arterial hypertension is a rare disease, general PH often complicates other pulmonary and cardiovascular diseases and is a relatively common entity. Significant differences and similarities exist between the five groups of PH, as defined by the World Health Organization. However, without clinical context and noninvasive tests, there is no sufficient evidence to provide an accurate diagnosis. This course will focus on the how to differentiate between the various PH groups and how to utilize integrative tests to produce an accurate and effective diagnosis and treatment plan.


  • Pediatric PAH Patients: How to Manage, How to Treat

    Course ID: 2824
    Course Author: Erika Rosenzweig




  • Pulmonary Function Testing in PH

    Course ID: 2971
    Course Author: James Lamberti

    Pulmonary Function Testing in PH Course Image
    Pulmonary function testing is a series of tests that measure how well the lungs take in and exhale air, and how efficiently they transfer oxygen into the blood. Following participation in this webinar, hosted by PHA Online University, participants will be able to understand the role of pulmonary function tests in the evaluation of a patient with PH, classify pulmonary function test abnormalities as obstructive or restrictive, and define the typical abnormalities of pulmonary function in patients with idiopathic PAH.


  • Pulmonary Hypertension and RV Failure in the ICU

    Course ID: 2972
    Course Author: Steven Pugliese

    Pulmonary Hypertension and RV Failure in the ICU C
    Following participation in this webinar, hosted by PHA Online University, participants will be able to utilize techniques to determine etiology of shock state; understand the roles of inotropes, vasopressors, and pulmonary vasodilators in acute right heart failure; discuss an approach to arrhythmias and mechanical ventilation in decompensated right heart failure; and discuss the role of mechanical circulatory support in right heart failure.


  • Rethinking Pediatric PH-International Aspects

    Course ID: 2813

    The past 30 years have produced tremendous advancements in the field of pulmonary hypertensive vascular disease (PHVD), particularly in pulmonary hypertension. The resultant improvements have bolstered patient quality of life and survival rates. In concert with this progress, there has been a renewed international effort amongst pediatric-focused clinicians to identify the similarities and differences between adult and pediatric patients and to highlight areas unique to the pediatric patient. This class will discuss these similarities and differences, with a particular emphasis on the Panama Classification for Pediatric Pulmonary Hypertensive Vascular Disease, and a focus its relevance to the pediatric patient.


  • Salvage Therapies in the U.S. and Europe versus Everywhere Else

    Course ID: 2812
    Course Author: Corey E. Ventetuolo
    Course Author: T. Pulido

    This session will focus on the definition and indications for interventional (surgical, non-surgical, and extracorporeal devices) strategies in patients with advanced PAH. It will discuss atrial septostomy, Pott's shunt, and current ECLS technologies as a bridging strategy to recovery or transplant in the context of global resources, restrictions, and limitations of organ donation.


  • The Accreditation Journey: PHCC Site Visit

    Course ID: 2906




  • Therapies for PAH: Transitions and Case Examples

    Course ID: 2820
    Course Author: Martha Kingman

    This class will discuss the basic principles for transitioning between PAH therapies. Several published transition methods will be presented. We will also be discussing helpful tips for managing side effects during transitions. The class will conclude with case studies describing transition methods used at the University of Texas Southwestern Medical Center at Dallas.


  • To SNF or Not to SNF: PH Therapies in Extended Care Facilities

    Course ID: 2789
    Course Author: Jacqueline Brewer
    Course Author: Jennifer Priziola
    Course Author: Samuel Allen

    Pulmonary arterial hypertension is a chronic disease beset by complications that may necessitate prolonged hospitalizations followed by the need for rehabilitation. However, many extended care facilities are not trained or able to manage the treatments for pulmonary arterial hypertension. In this session, we will discuss opportunities for error to occur during transitions of care, how to overcome them, and most importantly how to avoid them.


  • Transplanting in the PAH Patient: Screening and Evaluation for Lung Transplant

    Course ID: 2825
    Course Author: Fernando Torres

    The lung transplantation of a patient with PAH is very challenging. These patients carry the highest perioperative mortality of all lung transplant patients, but once the patients make it to one year, they tend to have one have one of the best long-term survivals. Thus, the selection of patients with PAH is critical for a successful transplant. In this section, we will concentrate on the screening and evaluation of patients with PAH to undergo lung transplantation.


  • Update on Classification, Screening, and Diagnosis of PH

    Course ID: 2815
    Course Author: C. Gregory Elliott




  • Updated Algorithm of PAH Treatment: Phrontline News

    Course ID: 2818
    Course Author: Mardi Gomberg-Maitland

    This course will discuss the current treatment algorithm based on guideline consensus. The new guidelines include the recently reported Phase 3 studies of macitentan, riociguat, and selexipeg. The session will cover general measures of care, and discuss monotherapy and combination therapy evidence-based data. The session will conclude with a discussion of remaining gaps in clinical care that need further evidence.


  • Variety is the Spice of Life: Combination Therapy for PAH

    Course ID: 2724
    Course Author: Martha Kingman
    Course Author: Steven Nathan

    In this session we will discuss expert consensus guidelines for the use of combination therapy in PAH. We will briefly review the combination therapy clinical trial data to date including results of the recent AMBITION trial. We will also discuss some drug-drug interactions between PH medications.


  • WHO Group 1 PH (PAH)

    Course ID: 2937
    Course Author: Anna Hemnes

    WHO Group 1 PH (PAH) Course Image
    Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension (PH) characterized by increases in both pulmonary arterial pressure and pulmonary vascular resistance (PVR). This educational activity will help participants a) differentiate PAH from other forms of PH; b) integrate diagnostic tests to improve accuracy in PAH diagnosis; c) describe risk factors for developing PAH; and d) recognize outcome differences between associated PAH and idiopathic/heritable PAH.


  • WHO Group 4 PH (CTEPH Treatment): Surgical vs. Medical

    Course ID: 2936
    Course Author: Richard Channick

    WHO Group 4 PH (CTEPH) Treatment: Surgical vs. Med
    For more than two decades, WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) has been treated surgically through pulmonary thromboendarterectomy (PTE). In late 2013, riociguat was approved by the U.S. Food & Drug Administration (FDA) for the treatment of inoperable or PH occurring post-PTE. Following this approval, expert consensus guidelines on the diagnosis and treatment of PH have incorporated medical management of these specific PH patients into the treatment algorithm. However, PTE remains the recommended intervention in patients deemed operable as it can hemodynamically stabilize correctly selected patients. These guidelines, however, remain vague about the definition of operability as it relies on the technical abilities of the surgical and medical multidisciplinary teams and a paucity of long-term, multi-center outcomes data. This session seeks to a) describe the role of CT angiography in assessing surgical accessibility in CTEPH patients; b) discern operable versus inoperable CTEPH; interpret the surgical classification system for CTEPH; d) explain the benefits of PTE; and e) discuss the therapeutic options for those patients with inoperable or recurrent CTEPH, including PH-targeted medical therapy and/or balloon pulmonary angioplasty.


  • WHO Group 4 PH (CTEPH)

    Course ID: 2934
    Course Author: William Auger

    WHO Group 4 PH (CTEPH) Course Image
    WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) is a rare disease characterized by a mean pulmonary artery pressure (mPAP) = 25 mmHg, pulmonary artery occlusion pressure = 15 mmHg, and chronic, organized emboli in the pulmonary artery. In this session, the CTEPH clinical definition, the role of screening in all PH patients, risk factors for developing CTEPH, and treatment options will be discussed.


  • What Has Happened in the Last 25 Years: Global Perspectives/ 20 Years of Prostacyclins

    Course ID: 2807
    Course Author: Vallerie McLaughlin

    When the Pulmonary Hypertension Association was founded 25 years ago, treatment options for PAH patients were significantly limited. Though a small percentage of patients were eligible for calcium channel blockers, the average patient was treated with diuretics, digoxin, or warfarin. Modern therapies now address the three, well-characterized pathologic pathways. This session will provide a perspective on the treatment of PAH over the past 25 years.


  • What Have We Learned from Modern Worldwide Registries?

    Course ID: 2808
    Course Author: David Badesch

    Over the past decade, researchers across the world have performed registry studies with pulmonary hypertension (PH) patients. While the extrapolated data from these studies is limited, the results provide impactful and useful knowledge as it pertains to disease awareness, diagnosis, clinical care, and clinical trial design. This course will examine the information derived from modern global registries and how it has impacted the world of PH.